A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Manmath Patekar, Adam Reich et al.|Journal of the American Academy of Dermatology|2021Cited by 50
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Manmath Patekar, Külli Kingo et al.|Pediatric Drugs|2022Cited by 19